Muldoon Matthew F, Mackey Rachel H, Korytkowski Mary T, Flory Janine D, Pollock Bruce G, Manuck Stephen B
Division of Clinical Pharmacology, Departments of Medicine and Epidemiology, University of Pittsburgh, 4015 O'Hara Street, Pittsburgh, PA 15260, USA.
J Clin Endocrinol Metab. 2006 Feb;91(2):718-21. doi: 10.1210/jc.2005-1654. Epub 2005 Nov 22.
The pathobiology of the metabolic syndrome remains unclear. The central nervous system is likely to be involved via regulation of eating, physical activity, blood pressure, and metabolism.
The objective of this study was to test the hypothesis that low central serotonergic activity is associated with the metabolic syndrome.
DESIGN, SETTING, PARTICIPANTS: This was a cross-sectional study of 345 healthy community volunteers, aged 30-55 yr, not taking medications for hypertension, lipid disorders, or diabetes.
Central serotonergic responsivity was assessed with the iv citalopram challenge test. The serum prolactin area under the curve (AUC) over 150 min was calculated, and all analyses were adjusted for age, sex, plasma citalopram concentration, and baseline prolactin. The metabolic syndrome was defined according to the National Cholesterol Education Program (NCEP) and International Diabetes Federation (IDF) criteria. Insulin resistance was estimated by homeostasis model assessment.
Compared with other individuals, persons meeting either NCEP or IDF criteria for the metabolic syndrome had lower mean prolactin responses (P < 0.05 for both). Using logistic regression, a decrease in prolactin AUC of 1 sd (-13.6 ng/ml.h) more than doubled the odds of having the metabolic syndrome (NCEP criteria: odds ratio, 2.38; 95% confidence interval, 1.14-4.97; P = 0.02; IDF criteria: odds ratio, 2.80; 95% confidence interval, 1.48-5.30; P = 0.002). Finally, the prolactin AUC was negatively associated with insulin resistance (beta = -0.03, P = 0.02).
Corroborating previous evidence, the metabolic syndrome was associated with diminished brain serotonergic activity as reflected in a comparative blunting of the prolactin response to a selective serotonergic challenge. This association may have implications for the etiology, prevention, and treatment of the metabolic syndrome.
代谢综合征的病理生物学机制仍不清楚。中枢神经系统可能通过对饮食、身体活动、血压和代谢的调节而参与其中。
本研究的目的是检验低中枢5-羟色胺能活性与代谢综合征相关的假说。
设计、地点、参与者:这是一项对345名年龄在30 - 55岁之间、未服用抗高血压、血脂异常或糖尿病药物的健康社区志愿者进行的横断面研究。
采用静脉注射西酞普兰激发试验评估中枢5-羟色胺能反应性。计算150分钟内血清催乳素曲线下面积(AUC),所有分析均针对年龄、性别、血浆西酞普兰浓度和基线催乳素进行了校正。根据美国国家胆固醇教育计划(NCEP)和国际糖尿病联盟(IDF)的标准定义代谢综合征。通过稳态模型评估估算胰岛素抵抗。
与其他个体相比,符合NCEP或IDF代谢综合征标准的人平均催乳素反应较低(两者P均<0.05)。采用逻辑回归分析,催乳素AUC下降1个标准差(-13.6 ng/ml·h)使患代谢综合征的几率增加一倍以上(NCEP标准:比值比,2.38;95%置信区间,1.14 - 4.97;P = 0.02;IDF标准:比值比,2.80;95%置信区间,1.48 - 5.30;P = 0.002)。最后,催乳素AUC与胰岛素抵抗呈负相关(β = -0.03,P = 0.02)。
与先前证据一致,代谢综合征与脑5-羟色胺能活性降低有关,这表现为对选择性5-羟色胺能激发的催乳素反应相对减弱。这种关联可能对代谢综合征的病因、预防和治疗具有重要意义。